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Introduction. Pleurotus sajor-caju (PSC) is an edible oyster mushroom featuring high nutritional values and pharmacological
properties. Objective. To investigate the hypoglycemic and antidiabetic effects of single and repeated oral administration of PSC
aqueous extract in normal and diabetic rats. Materials and Methods. A single dose of 500, 750, or 1000mg/kg of the PSC extract
was given to experimental rats to determine the effects on blood glucose (BG) and oral glucose tolerance test (OGTT).The effective
dose (750mg/kg) of PSC extract was repeatedly administrated daily for 21 days in diabetic rats to examine its antidiabetic effects in
terms of BG control, body weight, urine sugar, HbA1c, and several serum profiles. Results. The dose of 750mg/kg showed the most
significant BG reduction (23.5%) in normal rats 6 hours after administration in BG study (𝑝 < 0.05). In OGTT study, the same dose
produced a maximum BG fall of 41.3% in normal rats and 36.5% in diabetic rats 3 hours after glucose administration. In 21-day
study, treated diabetic rats showed significant improvement in terms of fasting BG, body weight, and urine sugar as compared to
control diabetic rats. Conclusion. The study evidenced scientifically the beneficial use of PSC as an alternative medicine in diabetes
management.
1. Introduction
Diabetes mellitus (DM) is a debilitating chronic metabolic
disorder featured by hyperglycemia due to defects in insulin
secretion, insulin action, or both [1]. Presently, there is a rapid
rise in the prevalence of DM, with the number of diabetic
individuals estimated to doubly increase from 171 million in
2000 to 366million in 2030 [2]. It is themajor cause ofmorbi-
dity andmortality worldwide as it may lead to health compli-
cations and affect quality of life [3].
Management of diabetes basically initiates with a mod-
ification in diet and exercise. Nonetheless, most diabetic
patients eventually require pharmacotherapy, such as injec-
tion of insulin and/or administration of oral antidiabetic
drugs. Many oral hypoglycemic drugs such as biguanides,
𝛼-glucosidase inhibitors, sulphonylurea, and thiazolidine-
diones are available for the DM treatment. These synthetic
drugs are the mainstay of treatment of diabetes and are effec-
tive in controlling hyperglycemia but they are not free from
harmful side effects such as hypoglycemia, hepatic toxicity,
weight increase, abdomen enlargement, and gastrointestinal
discomfort [4, 5].Therefore, development of safe and effective
oral hypoglycemic agents from medicinal plants to manage
DM without side effects is of great interest recently and is
strongly recommended by WHO [6]. In recent years, tradi-
tional Chinese medicine such as Ginkgo biloba extract and
crude extract from natural products such as Leguminosae,
Cucurbitaceae, and Araliaceae have been established scien-
tifically to have antidiabetic effects [7, 8].
Pleurotus sajor-caju (PSC), one of the species from Pleu-
rotus spp., is an edible oyster mushroom firstly discovered
in India and characterized by a white spore print and gills
attachment as well as eccentric stip occasionally [9]. It grows
on trunks and stumps of deciduous trees in tropical and
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subtropical rainforests and could be artificially cultivated
on various agricultural residues [10]. It ranks second most
popular cultivated mushrooms after button mushroom and
accounted for 14.2% of the total worldmushroom production
[11]. For centuries, it has been widely used for culinary and
medicinal purpose due to its pleasant taste and pharmaco-
logical properties.
This prominent edible oyster mushroom is claimed to
possess considerable importance in the human diet as it
shows favourable dietetic properties. It is attributed to its high
protein, minerals (calcium, phosphorus, and iron), B vita-
mins (thiamin, riboflavin, and folic acid), and dietary fiber
content [12]. On the other hand, it is low in fat content and
calorific value (kcal/g) and completely devoid of starch; hence
it could be an excellent inclusion in the diet of individuals
with hyperlipidemia and diabetes [13].Therefore, it is consid-
ered to be advantageous in the prevention and management
ofDM. Previously, attention has been focused primarily on its
immunemodulating, hypotensive, hypocholesterolemic, and
antitumor properties [14, 15]. Nevertheless, lack of scientific
information is available on its antidiabetic properties.
Thus, it was worthwhile to find out the scientific basis
for its utilization in diabetes management. This study aimed
at investigating the hypoglycemic and antidiabetic effects of
PSC aqueous extract by evaluating the glucose tolerance test
and certain important serum profiles in normal and STZ-
induced diabetic rats.
2. Materials and Methods
2.1. Preparation of PSC Aqueous Extract. Fresh fruiting bod-
ies of PSC (5 kg; pileus cap diameter between 9 and 11 cm)
were obtained from National Kenaf and Tobacco Board
(NKTB), Malaysia. It was identified and authenticated by the
authority in NKTB, Malaysia. After drying process, Biode-
hydration (the secret trade drying process done by Anjaad
industry, Malacca, Malaysia), the dehydrated PSC (yield:
10%w/w) were milled and sifted into fine powder having
diameter of 125 𝜇m. For the aqueous extract preparation,
20 g of PSC powder was extracted with 250mL of distilled
water by using Soxhlet apparatus (hot continuous extraction
method).This process was continuously carried out for 3 days
until a drop of distilled water did not leave residue when
evaporated. After the extract was cooled down, it was put
into screw cap bottle and freeze-dried to obtain PSC aqueous
extract (yield: 30%w/w).
2.2. Animals. Male Sprague-Dawley rats with body weight
of 250–300 g each were supplied from Animal Research and
Service Centre (ARASC), Universiti Sains Malaysia. They
were housed in polypropylene cages (1 rat in each cage)
in a room with controlled temperature (25∘C ± 2∘C) and
maintained in a light : dark (12 : 12) cycle. The rats were
provided with pellet diet and water ad libitum. Prior to
experimentation, they were acclimatized for a period of one
week. Male animals were chosen for most of the studies as
the females have appeared to be secured from lipid-induced
reductions in insulin action [16]. This study was permitted
by the Universiti Sains Malaysia Animal Ethics Committee
(USM/Animal Ethics Approval/2013/(85) (464)).
2.3. Induction of Diabetes. After one week of acclimatization,
freshly prepared Streptozotocin (STZ) (40mg/kg BW) in
0.1M citrate buffer (pH 4.5) has been administrated to
overnight-fasted rats by a single intraperitoneal injection
to induce diabetes [17]. Fasting blood glucose (FBG) level
was measured at the diabetes induction stage until stable
hyperglycemia, usually one week after STZ administration.
Diabetic rats were defined as those having FBG level exceed-
ing 8mmol/L.
2.4. Experimental Design. Initial screening of the PSC aque-
ous extract on examining its hypoglycemic potential was
conducted by BG study. Variable doses of 500, 750, and
1000mg/kg of extract were given orally by gavage in normal
rats. Besides, oral glucose tolerance test (OGTT) was also
performed in normal and diabetic rats with the mentioned
doses of the extract. By identifying the most effective dose
(750mg/kg) of PSC aqueous extract from previous experi-
ments, the antidiabetic effects of PSC aqueous extract were
assessed for 21 days in diabetic rats.This experimental design
was similar to that of studies described by [6, 18] with some
modifications.
2.4.1. Initial Screening of Hypoglycemic Activity of the Extract
in Normal Rats. Thirty overnight-fasted normal rats were
equally divided into five groups of six rats each. Group I (con-
trol) received vehicle (distilled water), whereas group II (pos-
itive control) receivedmetformin (150mg/kg). Variable doses
of PSC aqueous extract (500, 750, and 1000mg/kg) suspended
in distilled water were administrated orally to groups III, IV,
and V, respectively. Blood samples were then withdrawn at 2,
4, and 6 h to determine BG level after FBG measurement.
2.4.2. Assessment of Hypoglycemic Activity of the Extract by
OGTT in Normal Rats. Another group of thirty overnight-
fasted normal rats were equally divided and treated on
the previously mentioned approach. FBG was indicated at
the beginning and BG level was measured after 90min of
treatment expressed as “0” h value. Oral administration of
0.2 g/mL glucose solution at 1mL/100 g body weight (2 g/kg)
was delivered to all of the groups. BG level was further
measured, up to 3 h with 1 h intervals each, expressed as 1, 2,
and 3 h values.
2.4.3. Assessment of Hypoglycemic Activity of the Extract by
OGTT in Diabetic Rats. The hypoglycemic potential of PSC
aqueous extract in diabetic rats was evaluated in the glucose
tolerance test. Thirty overnight-fasted diabetic rats were
equally divided and also treated on the same pattern. The
protocol in conducting the OGTT study in diabetic rats was
the same as those for normal rats (in Section 2.4.2).
2.4.4. Assessment of Antidiabetic Activity of the Extract in
Diabetic Rats. Subacute study (21-day) of the effects of PSC
aqueous extract on antidiabetic properties was conducted in
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Table 1: Initial screening (BG study) of hypoglycemic effect of graded doses of PSC aqueous extract in normal rats (mean ± SD).
Experimental animals Treatment
Blood glucose levels (mmol/L)
Pretreatment level Posttreatment level
FBG 2 h 4 h 6 h
Normal (control) Distilled water 5.0 ± 0.1 4.9 ± 0.1 4.8 ± 0.1 4.7 ± 0.1
Normal (treated) Metformin (150mg/kg) 5.3 ± 0.3 4.6 ± 0.1 4.2 ± 0.1a 4.0 ± 0.1a
Normal (treated) PSCE (500mg/kg) 5.1 ± 0.2 4.8 ± 0.1 4.6 ± 0.2b 4.5 ± 0.1b
Normal (treated) PSCE (750mg/kg) 5.1 ± 0.2 4.4 ± 0.2 4.1 ± 0.3a 3.9 ± 0.2a
Normal (treated) PSCE (1000mg/kg) 5.2 ± 0.3 4.6 ± 0.2 4.3 ± 0.1 4.1 ± 0.1a
a
𝑝 < 0.05 as compared to normal control group (distilled water).
b
𝑝 < 0.05 as compared to normal treated group (metformin 150mg/kg).
PSCE, Pleurotus sajor-caju aqueous extract.
diabetic rats. Twenty-four rats were equally divided into four
groups of six rats each. Control groups (groups I and II) were
normal and diabetic rats receiving vehicle (distilled water).
Groups III and IV were both diabetic rats and treated with
the effective dose of 750mg/kg of the extract and 150mg/kg
of metformin as positive control, respectively. The allocated
treatment was administered orally to all of the groups by
gavage once daily in the morning for a period of 21 days.
FBG, urine sugar, and body weight (BW) were measured at
the beginning (0 days) and after 7, 14, and 21 days of the
experiment. At the end of the experiment, five milliliters of
blood was withdrawn by means of cardiac puncture (termi-
nal bleeding) under general anaesthesia (pentobarbitone
100mg/kg) from all of the experimental groups. Lipid pro-
files, renal function profiles, liver function profiles, and gly-
cated haemoglobin (HbA1c) were also analysed after the
experiment.
2.4.5. LD50 Experiment. Acute toxicity of PSC aqueous ext-
ract was examined by conducting LD
50
experiment. Sixteen
normal rats were equally divided into two groups of eight
rats each (4 males and 4 females). A single dose of either
5 (3.75 g/kg) or 10 (7.5 g/kg) times the PSC aqueous extract
effective dose was orally administrated to them.The rats were
then observed for gross behavioural, autonomic, neurologic,
and toxic effect for 24 h with short intervals of time. Food
consumption, faeces, and urine were also inspected at first 2 h
and then at 6 h intervals for 24 h.
2.5. Estimations. Blood samples were withdrawn bymeans of
tail artery prick method to measure BG level (mmol/L) using
glucometer (Accu-Check Performa, Roche). Body weight
(g) of rats was measured gravimetrically using analytical
balance. Urine sugar levels were detected by Combur test
from Roche Diagnostics. HbA1c (%) levels were determined
by using Cobas Integra 800 analyser based on Turbidimet-
ric Inhibition Immunoassay (TINIA) method. Lipid, renal
function and kidney function profiles were determined by
using Architect (Abbott brand, Ci8000) analyser based on
enzymatic photometric method.
2.6. Statistical Analysis. Data obtained were tested for signif-
icance using two-way repeated measures analysis of variance
(ANOVA) followed by Bonferroni’s Multiple Comparison
Test. The data were analysed by using GraphPad Prism ver-
sion 6.0 for windows (GraphPad Software, San Diego, Cal-
ifornia, USA). Results were expressed as mean ± standard
deviation. Significant differences have been only established
if 𝑝 < 0.05.
3. Results
3.1. Hypoglycemic Effect of PSC Aqueous Extract on BG in
Normal Rats. Results from initial screening of hypoglycemic
effect of graded doses of PSC aqueous extract in normal rats
are presented in Table 1. Generally, all rats showed reduction
on BG level 6 h after administration. The doses of 750 and
1000mg/kg PSC extract produced significant (𝑝 < 0.05)
reduction of BG level compared to vehicle control but
established no significant difference compared to metformin
as positive control. Hence, the PSC extract has been demon-
strated to have similar hypoglycemic effect as that of metfor-
min. Moreover, 6 h after administration, it was noticed that
the rats treated with 750mg/kg of PSC extract produced the
highest maximum fall (23.5%) in BG level among all PSC
extract-treated groups, whereas the fall of 11.8 and 21.2% was
observed with the doses of 500 and 1000mg/kg, respectively.
In the aspect of time frame, 750mg/kg dose started to report
significant reduction in BG level 4 h after administration;
meanwhile 1000mg/kg dose showed significant reduction in
BG level only 6 h after administration. It could be stated
that dose of 750mg/kg documented more immediate hypo-
glycemic effect than that of 1000mg/kg. Hence, 750mg/kg
dose was selected to be the most effective dose of PSC extract
from this BG study.
3.2. Hypoglycemic Effect of PSC Aqueous Extract on OGTT in
Normal Rats. In order to determine themost effective dose of
PSC aqueous extract on glucose tolerance in normal rats,
variable doses (500, 750, and 1000mg/kg) of PSC extract were
examined along with metformin (150mg/kg) as standard
drug and the effects were depicted up to 3 h after glucose
administration (Figure 1). Rats treated with the doses of 750
and 1000mg/kg significantly (𝑝 < 0.05) produced the lower
BG level peak in comparison to vehicle control group 1 hr
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Figure 1: Hypoglycemic effect of graded doses of PSC aqueous
extract on glucose tolerance in normal rats. a𝑝 < 0.05 as compared to
normal control group (distilled water); b𝑝 < 0.05 as compared to
normal treated group (metformin 150mg/kg). PSCE, Pleurotus
sajor-caju aqueous extract.
after glucose loading. The effect of the doses also demon-
strated no significant difference compared to metformin
group. However, it was more apparent in rats receiving
750mg/kg of the PSC extract. This dose brought a raise of
63.3%, which is the lowest increment of BG level compared
to 76.0 and 65.3% in 500 and 1000mg/kg, respectively. Apart
from that, 3 h after glucose loading, BG level of rats treated
with the doses of 750 and 1000mg/kg PSC extract was
reduced significantly (𝑝 < 0.05) compared to vehicle control
but there was no significant difference compared to met-
formin. The dose of 750mg/kg exhibited a maximum fall of
41.3%, whereas the fall of 39.8 and 40.7% was documented
with the doses of 500 and 1000mg/kg, respectively.
3.3. Hypoglycemic Effect of PSC Aqueous Extract on OGTT in
Diabetic Rats. The above-mentioned variable doses of PSC
extract were given to diabetic rats and the hypoglycemic
effects were evaluated along with the standard drug met-
formin.The result of glucose tolerance test up to 3 h of glucose
loadingwas illustrated in Figure 2. For the 500mg/kg as lower
dose, the BG level reported no significant difference com-
pared to control treatment 1 h after glucose administration,
indicating no hypoglycemic effect. However, diabetic rats
treated with 750 and 1000mg/kg of the PSC extract signifi-
cantly (𝑝 < 0.05) exhibited the lower BG level peak compared
to vehicle control group and produced no significant differ-
ence compared to metformin group. Besides, the BG level
peak increment degree of 750 (74.7%) and 1000mg/kg (73.1%)
was also lower if compared to 500mg/kg dose (97.7%). 3 h
after glucose loading, BG level of rats treated with the doses
of 750 and 1000mg/kg PSC extract documented significant
reduction (𝑝 < 0.05) compared to vehicle control but
there was no significant difference compared to metformin.
The dose of 750mg/kg exhibited a maximum fall of 36.5%,



































Figure 2: Hypoglycemic effect of graded doses of PSC aqueous
extract on glucose tolerance in diabetic rats. a𝑝 < 0.05 as compared
to diabetic control group (distilled water); b𝑝 < 0.05 as compared
to diabetic treated group (metformin 150mg/kg). PSCE, Pleurotus
sajor-caju aqueous extract.
whereas the fall of 33.5 and 34.8%was reportedwith the doses
of 500 and 1000mg/kg, respectively.
3.4. Antidiabetic Effects of PSC Aqueous Extract on FBG, Body
Weight, Urine Sugar, and Several Important Serum Profiles in
Diabetic Rats (Long Term Study). It was attempted to indicate
the effect of subacute repeated oral administration of the PSC
extract on FBG, bodyweight, and urine sugar in STZ-induced
diabetic rats (Table 2). The parameters were measured before
and after 7, 14, and 21 days of treatment. Generally, the PSC
extract and metformin exhibited gradual FBG reduction in
diabetic rats, whereas FBG increment was detected in control
diabetic group throughout the study. After 14-day treatment
period, FBG of diabetic rats treated with PSC extract was
decreased by 5% and further decreased by 6.9% after 21
days significantly (𝑝 < 0.05). The FBG reduction effect of
metforminwas shown better and earlier than the PSC extract,
in which it started to show FBG reduction significantly after
7 days of treatment (7.7%; 𝑝 < 0.05). In comparison to
all groups, diabetic rats treated with PSC extract reported
significant (𝑝 < 0.05) reduction of FBG compared to control
diabetic rats after 14 and 21 days of treatment. At the same
time, their FBG also showed significant difference (𝑝 < 0.05)
compared to metformin group. It is indicated that the PSC
extract possesses significant FBG reduction effect but the
effect was not comparable to standard drug metformin.
In the aspect of body weight, metformin group showed
body weight increment; meanwhile groups of control and
PSC extract treatment reported gradual degradation of body
weight throughout the study. Body weight of PSC extract-
treated group showed significant (𝑝 < 0.05) degradation
every 7 days, with 7.1% degradation after 21 days of treatment.
In comparison to all groups, PSC extract-treated diabetic
group reported no significant difference compared to control
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Table 2: Antidiabetic effects of oral administration of PSC aqueous extract on FBG, body weight, and urine sugar in diabetic rats (mean ±
SD).
Experimental animals Treatment Pretreatment level Posttreatment level
0 days 7 days 14 days 21 days
FBG (mmol/L)
Normal (control) Distilled water 5.5 ± 0.2 5.7 ± 0.2 5.4 ± 0.1 5.5 ± 0.2
Diabetic (control) Distilled water 10.2 ± 0.3 10.4 ± 0.2 10.2 ± 0.3 10.9 ± 0.4
Diabetic (treated) Metformin (150mg/kg) 10.4 ± 0.2 p9.6 ± 0.1a pq8.9 ± 0.3a p8.9 ± 0.3a
Diabetic (treated) PSCE (750mg/kg) 10.1 ± 0.2 10.0 ± 0.3 p9.6 ± 0.2ab pq9.4 ± 0.2ab
Body weight (g)
Normal (control) Distilled water 299.3 ± 9.9 327.3 ± 9.5 pq364.8 ± 4.1 pqr403.3 ± 6.7
Diabetic (control) Distilled water 279.3 ± 5.4 270.5 ± 3.1 p258.3 ± 7.4 pqr245.5 ± 6.0
Diabetic (treated) Metformin (150mg/kg) 282.3 ± 2.5 p295.8 ± 2.9a p308.3 ± 2.2a pqr318.5 ± 1.3a
Diabetic (treated) PSCE (750mg/kg) 275.8 ± 4.6 p269.5 ± 4.7b pq264.5 ± 4.7b pqr256.3 ± 2.1ab
Urine sugar (g/L)
Normal (control) Distilled water 0 0 0 0
Diabetic (control) Distilled water +2 +2 +2 +2
Diabetic (treated) Metformin (150mg/kg) +2 +1 0 0
Diabetic (treated) PSCE (750mg/kg) +2 +2 +1 +1
a
𝑝 < 0.05 as compared to diabetic control group (distilled water).
b
𝑝 < 0.05 as compared to diabetic treated group (metformin 150mg/kg).
p
𝑝 < 0.05 as compared to pretreatment level (0 days).
q
𝑝 < 0.05 as compared to 7 days.
r
𝑝 < 0.05 as compared to 14 days.
PSCE, Pleurotus sajor-caju aqueous extract.
diabetic group after 7 and 14 days of extract treatment. Nev-
ertheless, there was significant difference (𝑝 < 0.05) detected
between control and PSC extract-treated groups after 21 days
of treatment. The results indicated that 21-day treatment
of PSC extract maintained body weight of rats which was
dropped initially.
Basically, PSC extract-treated diabetic group showed
lower urine sugar compared to control diabetic groups but
still not comparable tometformin group during this subacute
study. For PSC extract-treated diabetic group, the urine sugar
was reduced by 50% after 14 days of extract treatment and
maintained the fall until the end of experiment.
After blood was withdrawn bymeans of cardiac puncture
(terminal bleeding) at the end of experiment, several serum
profiles were determined and results of all groups were
compared (Table 3). Lipid profiles (total cholesterol, HDL
cholesterol, LDL cholesterol, and triglyceride) of diabetic rats
treated with PSC extract reported no significant difference
compared to control and metformin-treated diabetic rats.
However, compared to diabetic control group, there was
slight improvement shown on the lipid profiles even though
no marked antihypercholesterolemic effects of PSC extract
were observed in diabetic rats. Moreover, analysed renal
function profiles (urea, creatinine, and uric acid) and liver
function profiles (albumin, globulin, and total bilirubin) of all
groups reported similar trend of result to that of lipid profiles,
in which there was no significant difference compared to
other groups. In terms of HbA1c, diabetic rats treated with
PSC extract documented lower reading with 6.5% reduction
observed compared to control diabetic rats. From the above
experimental outcome, it could be stated that long term treat-
ment of the PSC extract did not possess significant antidia-
betic properties but it exhibited more or less improvement in
terms of the important serum profiles in diabetes.
3.5. LD50 Experiment. Up to 5 and 10 times the effective dose
of PSC aqueous extract, the behaviour of all the treated rats
appeared to be normal. Furthermore, therewas no toxic effect
documented and no death occurred in all treated rats.
4. Discussion
The intention of this research was to investigate the effects of
PSC aqueous extract on glycemic control, glucose tolerance,
body weight, urine sugar, HbA1c, and lipid, renal function as
well as liver function profiles. STZ-induced diabetic rat was
used as a useful experimental model as it established diabetes
properties [19]. Metformin (positive control) was used
because it is one of the standard drugs used for management
of diabetes.
Pleurotus sajor-caju aqueous extract reduced BG level
in normal rats during initial screening. Besides, it also
significantly ameliorated glucose tolerance in normal and
diabetic rats by minimizing the high BG level peak after glu-
cose loading. This indicated that PSC extract has favourable
effects in bringing down the complications such as glucose
intolerance and preventing severity of diabetes. From the
above acute single administration study, the most optimum
effective dose was 750mg/kg which was selected for long
term repeated treatment study. It is because 750mg/kg dose
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Table 3: Antidiabetic effects of oral administration of PSC aqueous extract on lipid profiles, liver function profiles, kidney function profiles,
and HbA1c in mild diabetic rats (mean ± SD).
Experimental animals Treatment 21 days Posttreatment level
Total cholesterol (mmol/L)
Normal (control) Distilled water 1.5 ± 0.0
Diabetic (control) Distilled water 1.9 ± 0.2
Diabetic (treated) Metformin (150mg/kg) 1.7 ± 0.1
Diabetic (treated) PSCE (750mg/kg) 1.8 ± 0.1
HDL cholesterol (mmol/L)
Normal (control) Distilled water 1.2 ± 0.1
Diabetic (control) Distilled water 1.5 ± 0.1
Diabetic (treated) Metformin (150mg/kg) 1.4 ± 0.1
Diabetic (treated) PSCE (750mg/kg) 1.4 ± 0.2
LDL cholesterol (mmol/L)
Normal (control) Distilled water 0.2 ± 0.1
Diabetic (control) Distilled water 0.4 ± 0.1
Diabetic (treated) Metformin (150mg/kg) 0.2 ± 0.1
Diabetic (treated) PSCE (750mg/kg) 0.3 ± 0.0
Triglyceride (mmol/L)
Normal (control) Distilled water 0.5 ± 0.2
Diabetic (control) Distilled water 0.6 ± 0.2
Diabetic (treated) Metformin (150mg/kg) 0.5 ± 0.1
Diabetic (treated) PSCE (750mg/kg) 0.6 ± 0.1
Urea (mmol/L)
Normal (control) Distilled water 7.0 ± 0.5
Diabetic (control) Distilled water 8.1 ± 0.3
Diabetic (treated) Metformin (150mg/kg) 7.4 ± 0.5
Diabetic (treated) PSCE (750mg/kg) 8.1 ± 0.3
Creatinine (𝜇mol/L)
Normal (control) Distilled water 51.8 ± 2.6
Diabetic (control) Distilled water 61.6 ± 0.0
Diabetic (treated) Metformin (150mg/kg) 54.6 ± 2.3
Diabetic (treated) PSCE (750mg/kg) 58.3 ± 2.1
Uric acid (𝜇mol/L)
Normal (control) Distilled water 188.3 ± 13.1
Diabetic (control) Distilled water 192.2 ± 13.0
Diabetic (treated) Metformin (150mg/kg) 191.8 ± 10.4
Diabetic (treated) PSCE (750mg/kg) 190.7 ± 15.6
Albumin (g/L)
Normal (control) Distilled water 25.1 ± 1.6
Diabetic (control) Distilled water 22.4 ± 1.5
Diabetic (treated) Metformin (150mg/kg) 23.7 ± 1.6
Diabetic (treated) PSCE (750mg/kg) 22.1 ± 1.8
Globulin (g/L)
Normal (control) Distilled water 38.7 ± 1.9
Diabetic (control) Distilled water 34.0 ± 2.3
Diabetic (treated) Metformin (150mg/kg) 35.9 ± 2.5a
Diabetic (treated) PSCE (750mg/kg) 35.1 ± 2.6
Total bilirubin (𝜇mol/L)
Normal (control) Distilled water 1.7 ± 0.0
Diabetic (control) Distilled water 3.1 ± 0.2
Diabetic (treated) Metformin (150mg/kg) 1.7 ± 0.0a
Diabetic (treated) PSCE (750mg/kg) 2.7 ± 0.5
HbA1c (%)
Normal (control) Distilled water 3.7 ± 0.1
Diabetic (control) Distilled water 6.2 ± 0.3
Diabetic (treated) Metformin (150mg/kg) 3.9 ± 0.2a
Diabetic (treated) PSCE (750mg/kg) 5.8 ± 0.5
a
𝑝 < 0.05 as compared to diabetic control group (distilled water).
PSCE, Pleurotus sajor-caju aqueous extract.
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showed the maximum reduction (23.5%) in BG level in FBG
test and maximum improvement in OGTT particularly 1 and
2 h after administration of PSC extract. It is proposed thereby
that the active compounds of the PSC extract or its metabo-
lites may take approximately 120 minutes to perform their
hypoglycemic effect in the target tissues. Moreover, it also
produced comparable effect as of synthetic drug metformin
(150mg/kg). Nevertheless, the higher dose (1000mg/kg) of
PSC extract given did not report better hypoglycemic effects.
The situation of less hypoglycemic potential at increasing
dose is common with indigenous plant and has already been
discovered inCynodon dactylon [6],Moringa oleifera [18], and
Trichosanthes dioica [20]. This phenomenon might be due to
insufficient amount of active compound present in the extract
[18].
During subacute treatment, significant improvement in
FBG, body weight, and urine sugar was documented in
diabetic rats treated with PSC extract. It was evidenced that
FBG of diabetic rats treated with PSC extract was decreased
significantly by 6.6% after 21 days and showed significant
reduction compared to control diabetic rats within 14 days.
Besides, body weight and urine sugar of PSC extract-treated
group showed significant degradation (7.1%) after 21 days and
decrement by 50% after 14 days of extract treatment, respec-
tively. Elevated levels of FBG and urine sugar as well as redu-
ced bodyweight are basically associatedwith diabetes.Hence,
improvement of these diabetes characteristics indirectly jus-
tified the antidiabetic activity of the PSC extract.
Streptozotocin selectively damages pancreatic insulin-
secreting 𝛽-cells leading to diabetes [19]. Occurrences of
hyperlipidemia and kidney disease are the complications
caused by diabetes [21]. For serum profiles analyses, lipid,
renal function and liver function profiles of PSC extract-
treated diabetic rats showed slight improvement compared to
control diabetic rats despite being not significant. It is sug-
gested that the PSC extract could bring more or less antidi-
abetic effects in the studied serum profiles. Hence, the PSC
extract could be fundamental agent in overcoming complica-
tions caused by diabetes.This finding is in line with Pleurotus
ostreatus, a type of oyster mushroom which has been exam-
ined to have beneficial effect on glycemic control and lipid
profile [13]. Furthermore, a similar hypoglycemic effect was
observed on Agaricus bisporus (white button mushroom).
It has a positive influence on lipid metabolism and liver
function [22]. In order to ensure that the PSC is safe to be
consumed, acute toxicity study (LD
50
) was performed. High
LD
50
of PSC aqueous extract denotes its highmargin of safety.
Nutritional investigation of PSC reveals the presence of
high content of dietary fiber (35.6%) including 𝛽-glucan
(3.57%) [23]. These principles are recognized to be hypo-
glycemic and antidiabetic agents in diabetes management.
Dietary fiber and 𝛽-glucan have scientifically proven its syn-
ergistic effects and protective effects against various diseases
such as heart disease, stroke, and diabetes as they have the
potential to play an adjunctive role in reducing cholesterol
and BG levels [24]. In detail, 𝛽-glucan is a soluble dietary
fiber which can form viscous solution; thus it is resistant to
stomach digestive enzyme and delays glucose absorption in
intestine as well as gastric emptying rate [25]. Therefore, it
may slow down the rise in BG level after administration of
PSC aqueous extract, resulting in improvement of glucose
tolerance. Apart from that, glucan-rich polysaccharides from
PSCwere also reported to prevent glucose intolerance, insulin
resistance, and inflammation in mice fed with high-fat diet
[26].
5. Conclusion
The present study concludes that PSC aqueous extract has
demonstrated significant effects on BG level and apparent
improvement on glucose tolerance in single administration
study. This means that the PSC extract could give immediate
hypoglycemic effect such as reduced postprandial glycemic
response. For the subacute study with daily repeated admin-
istration of the extract, there were also some improvements
or less severe conditions in all measured parameters. In
addition, the PSC extract has been proven to be safely con-
sumed even up to 10 times the most effective dose. These
results evidently express the possible benefits of PSC aqueous
extract in controlling diabetes and preventing its compli-
cations. Further biochemical, pharmacological, and clinical
investigations should be undertaken to elucidate the possible
mechanism of the hypoglycemic and antidiabetic activities of
PSC aqueous extract.
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